Last reviewed · How we verify

NCT04856605

Umblical Pilonidal Sinus Evaluation

Completed Last updated 6 March 2024
What this trial tests

trial testing surgery in Pilonidal Sinus in 82 participants. Completed in 31 December 2020.

Timeline
1 January 2012
Primary endpoint
31 December 2020
31 December 2020

Quick facts

Lead sponsorIstanbul Medeniyet University
StatusCompleted
Study typeOBSERVATIONAL
Enrollment82
Start date1 January 2012
Primary completion31 December 2020
Estimated completion31 December 2020

Drugs / interventions tested

Conditions studied

Sponsor

Istanbul Medeniyet University

Who can join

Adults 15 to 80, any sex, with Pilonidal Sinus. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Purpose: Pilonidal sinus disease (PSD) is a chronic inflammatory condition of skin due to implanted loose hair. PSD is commonly seen in sacrococcygeal region, but can also be seen in axilla, perineum, suprapubic regions, on hands and umbilicus. The aim of this project was to find factors influencing the development and treatment of umbilical pilonidal sinus. Material and methods: In this cross-sectional prospective study, the investigators evaulated 82 (19 female, 63 male) patients with a history of umbilical pilonidal disease (e.g. predisposing factors, treatment modalities) between 2012 and 2020.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of surgery

Trials testing the same drug.

Other recruiting trials for Pilonidal Sinus

Currently open trials in the same condition.

Other Istanbul Medeniyet University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04856605.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing